Table 1. General characteristic of the study groups.
| Feature | ePD (n = 22) mean±SD |
aPD LID+ (n = 28) mean±SD | aPD LID- (n = 23) mean±SD |
|---|---|---|---|
| Age (years) | 62.1±10.9 (range:38–84) |
59.1±12.1 (range:35–80) |
66±12.1 (range:29–83) |
| Sex (males/females) | 11/11 | 11/17 | 13/10 |
| Disease duration (years) | 1.9±1.3 | 9.1±4.4 | 8.9±4.5 |
| LED/day | 329.8±230.6 (range: 0–700) |
1090.6±434.1 (range: 160–2040) |
1032.6 ±505.9 (range: 405–2240) |
| UPDRS I-IV score * | 21.4±13.8 | 34.4±14.3 | 33.8±13.7 |
LED- levodopa equivalent dose taken daily. UPDRS- Unified Parkinson’s Disease Rating Scale. ePD- early Parkinson’s disease stadium; aPD-advanced Parkinson’s disease stadium; LID- levodopa-induced dyskinesia.
* Part III of UPDRS was assessed in “on” period.